IDEXX Laboratories, Inc. (NASDAQ:IDXX) has been under significant scrutiny by investors and analysts recently. Some institutions like 1832 Asset Management L.P., Public Employees Retirement Association of Colorado, and Beacon Pointe Advisors LLC have trimmed their stakes in IDEXX. Contrarily, firms such as Morningstar Investment Services LLC, The Manufacturers Life Insurance Company, and US Bancorp DE have increased their holdings. Despite missed earnings for Q1 2024, IDEXX presented a strong EPS. The company is experiencing underperformance compared to its competitors. However, potential investors are still considering it due to its sound fundamentals and strong financial performance. The expansion of IDEXX's Catalyst platform and the introduction of the IDEXX inVue Dx cellular analyzer signifies its innovation in the biotech market. Despite a temporary drawdown from its July highs, the company has seen a rebound and continues to maintain a solid balance sheet. The projection of growth for IDEXX comes in light of the aging pet population identified as a 'solid longer-term tailwind' by an analyst. However, insider selling could indicate a sign of caution. It is also worth noting the continued global growth of IDEXX, despite persisting currency issues.
Idexx Laboratories IDXX News Analytics from Fri, 15 Sep 2023 07:00:00 GMT to Sun, 09 Jun 2024 16:35:12 GMT -
Rating 3
- Innovation 7
- Information 6
- Rumor -2